Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Aug 1;22(15):3038-47.
doi: 10.1093/hmg/ddt160. Epub 2013 Apr 9.

Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel

Affiliations

Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel

Mine S Cicek et al. Hum Mol Genet. .

Abstract

Ovarian cancer remains the leading cause of death in women with gynecologic malignancies, despite surgical advances and the development of more effective chemotherapeutics. As increasing evidence indicates that clear-cell ovarian cancer may have unique pathogenesis, further understanding of molecular features may enable us to begin to understand the underlying biology and histology-specific information for improved outcomes. To study epigenetics in clear-cell ovarian cancer, fresh frozen tumor DNA (n = 485) was assayed on Illumina Infinium HumanMethylation450 BeadChips. We identified a clear-cell ovarian cancer tumor methylation profile (n = 163) which we validated in two independent replication sets (set 1, n = 163; set 2, n = 159), highlighting 22 CpG loci associated with nine genes (VWA1, FOXP1, FGFRL1, LINC00340, KCNH2, ANK1, ATXN2, NDRG21 and SLC16A11). Nearly all of the differentially methylated CpGs showed a propensity toward hypermethylation among clear-cell cases. Several loci methylation inversely correlated with tumor gene expression, most notably KCNH2 (HERG, a potassium channel) (P = 9.5 × 10(-7)), indicating epigenetic silencing. In addition, a predicted methylation class mainly represented by the clear-cell cases (20 clear cell out of 23 cases) had improved survival time. Although these analyses included only 30 clear-cell carcinomas, results suggest that loss of expression of KCNH2 (HERG) by methylation could be a good prognostic marker, given that overexpression of the potassium (K(+)) channel Eag family members promotes increased proliferation and results in poor prognosis. Validation in a bigger cohort of clear-cell tumors of the ovary is warranted.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Clustering heat map of methylation in ovarian cancer. Results from the methylation profile analysis of the replication sets. The dendrogram on the left indicates methylation class relationships. Figures to the left are heat maps with methylation values expressed as methylated (blue) and unmethylated (yellow); rows represent subjects, which are grouped by predicted class membership (red lines), and columns represent the 22 CpG loci in hierarchical clustering order that were used to generate the methylation classes. Figures to the right are bar plots depicting the percent clear-cell/non-clear-cell cases across the predicted methylation classes, with numbers on the right representing the numbers of cases in each predicted methylation class. (A) Replication set 1 (n = 163) and (B) Replication set 2 (n = 159).

Similar articles

Cited by

References

    1. Del Carmen M.G., Birrer M., Schorge J.O. Clear cell carcinoma of the ovary: a review of the literature. Gynecol. Oncol. 2012;126:481–490. doi:10.1016/j.ygyno.2012.04.021. - DOI - PubMed
    1. Pearce C.L., Templeman C., Rossing M.A., Lee A., Near A.M., Webb P.M., Nagle C.M., Doherty J.A., Cushing-Haugen K.L., Wicklund K.G., et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol. 2012;13:385–394. doi:10.1016/S1470-2045(11)70404-1. - DOI - PMC - PubMed
    1. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012;460:237–249. doi:10.1007/s00428-012-1203-5. - DOI - PubMed
    1. Ozols R.F. Systemic therapy for ovarian cancer: current status and new treatments. Semin. Oncol. 2006;33:S3–S11. doi:10.1053/j.seminoncol.2006.03.011. - DOI - PubMed
    1. Romero I., Bast R.C., Jr Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology. 2012;153:1593–1602. doi:10.1210/en.2011-2123. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances